CTOs on the Move

Relmada

www.relmada.com

 
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.relmada.com
  • 880 Third Avenue 12th Floor
    New York, PA USA 10022
  • Phone: 646.876.3459

Executives

Name Title Contact Details

Similar Companies

Eastern Health

Eastern Health is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Eastern Health is based in St. John'S, NL. You can find more information on Eastern Health at www.easternhealth.ca

CareZone

CareZone is a social utility serving individuals and families that care for children, parents or loved ones. CareZone provides a safe, simple, accessible place to organize the information, and coordinate the people and processes involved in caring for someone in need. Co-founded by Jonathan Schwartz and Walter Smith, CareZone is based in San Francisco and Seattle.

Hitachi Chemical Research Ctr.

Hitachi Chemical Research Ctr. is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharos Life

Pharos Life is a Cambridge, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.